Cas:500-65-2 Rhapontigenin manufacturer & supplier

Chemical Name:Rhapontigenin

CAS.NO:500-65-2

Synonyms:trans-1-(3,5-Dihydroxyphenyl)-2-(3-hydroxy-4-methoxyphenyl)ethylene;5-[(E)-2-(3-Hydroxy-4-methoxyphenyl)vinyl]-1,3-benzenediol;rhapontigenin;5-[(E)-2-(3-Hydroxy-4-methoxyphenyl)vinyl]benzene-1,3-diol;(E)-5-(3-Hydroxy-4-methoxystyryl)benzene-1,3-diol;1,3-Benzenediol, 5-[(E)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]-;3,3′,5-Trihydroxy-4′-methoxy-trans-stilbene;5-[(E)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]benzene-1,3-diol

Molecular Formula:C₁₅H₁₄O₄

Molecular Weight:258.269

HS Code:

Physical and Chemical Properties:

Melting point:186-187ºC

Boiling point:503.6±38.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.722

PSA:69.92000

Exact Mass:258.089203

LogP:2.82

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like trans-1-(3,5-Dihydroxyphenyl)-2-(3-hydroxy-4-methoxyphenyl)ethylene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-[(E)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]benzene-1,3-diol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(E)-5-(3-Hydroxy-4-methoxystyryl)benzene-1,3-diol Use and application,5-[(E)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]benzene-1,3-diol technical grade,usp/ep/jp grade.

Related News: During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. 1,2-oxazolidine manufacturers During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. 4-Methoxy-2,6-dimethylbenzoic acid suppliers Brian McNamara, currently head of GSK’s consumer healthcare division, will continue to serve as the franchise’s CEO after it breaks away from GSK in 2022, the British pharma said Thursday. 7-Epi-docetaxel vendor & factory Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.”,During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031.